Education
About Us
Working with TipRanks
Follow Us
Syra Health Corp. Class A (SYRA)
OTHER OTC:SYRA
Top Page
Syra Health Corp. Class A
(OTC:SYRA)
Rating:50Neutral
Price Target:
$0.00
▼(-100.00%Downside)
Syra Health Corp. Class A (SYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.43M
Dividend YieldN/A
Average Volume (3M)32.48K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth33.04%
EPS Growth39.30%
CountryUS
Employees57
SectorHealthcare
Sector Strength40
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.04
Shares Outstanding11,339,169
10 Day Avg. Volume16,439
30 Day Avg. Volume32,477
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-1.04
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-1.23
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Syra Health Corp. Class A Business Overview & Revenue Model
Company DescriptionSyra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.
How the Company Makes MoneySyra Health Corp. generates revenue primarily through its digital health platforms, healthcare consultancy services, and data management solutions. These platforms and services are offered to healthcare providers, hospitals, and other medical institutions seeking to improve their operational efficiencies and patient outcomes. Revenue streams include subscription fees for digital health platforms, consulting fees for bespoke healthcare solutions, and contractual agreements for data analytics services. Key partnerships with medical institutions and technology firms also contribute to the company's earnings by expanding its market reach and enhancing its service offerings. Additionally, Syra Health may engage in strategic alliances and collaborations to further diversify its income through joint ventures and co-developed health technology products.
Syra Health Corp. Class A Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 50.00%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with significant achievements in revenue growth, margin expansion, and operational efficiencies. However, challenges such as the NASDAQ delisting, decline in Healthcare Workforce revenue, and federal funding uncertainties were notable concerns. The balance of positive and negative elements suggests a cautious outlook.Q1-2025 Updates
Positive Updates
Revenue Growth and Strong Performance in Population Health
Syra Health delivered total revenue of $1.9 million, reflecting 6% annual growth compared to the first quarter of 2024. The Population Health business unit more than tripled its revenue year-over-year and represented 65% of total revenue.
Gross Margin Expansion
Gross margin expanded by 14.6 percentage points to 31.7% due to increased contribution from the Population Health unit and milestone-driven projects.
Operating Expense Reduction
Operating expenses declined by 39% year-over-year, driven by workforce optimization and expense management policies.
Net Loss Improvement
Net loss for the first quarter of 2025 improved over two-thirds to $472,000, compared to a net loss of $1.4 million in the first quarter of 2024.
Expansion in Behavioral and Mental Health
The Syrenity App, focused on mental health, is experiencing increased demand and initial adoption, with new content aimed at supporting individuals with PTSD.
Negative Updates
Delisting from NASDAQ
Syra Health announced a voluntary delisting from the NASDAQ capital market to focus on core fundamentals and reduce costs associated with the NASDAQ listing.
Healthcare Workforce Revenue Decline
Healthcare Workforce revenue was $655,000 in Q1 2025, down from $1.4 million in the previous year, as the company phases out contracts with unfavorable unit economics.
Federal Funding Uncertainty
Federal-level changes are impacting funding for key government customers, resulting in paused, reinstated, or cut projects, leading to potential short-term revenue and cash flow challenges.
Outlook Withdrawal
Due to uncertain impacts of federal developments, Syra Health has withdrawn its previously issued guidance for revenue growth and profitability for the full year of 2025.
Company Guidance
During the first quarter of 2025, Syra Health demonstrated notable financial momentum, achieving a 6% increase in total revenue to $1.9 million compared to the same period in 2024. This growth was largely driven by the Population Health business unit, which saw a 261% year-over-year increase and accounted for 65% of total revenue. The gross margin improved significantly by 14.6 percentage points to 31.7%. Operating expenses were reduced by 39%, resulting in a narrowed net loss of $472,000, down from $1.4 million in the previous year. Despite federal funding uncertainties impacting state and local government contracts, the company remains focused on high-margin revenue streams and private sector expansion. Consequently, Syra Health withdrew its previous guidance for 2025 due to limited visibility into federal-level changes, but maintains an optimistic outlook for long-term growth.Syra Health Corp. Class A Financial Statement Overview
Summary
Syra Health Corp. shows strong revenue growth but struggles with profitability and cash flows. The balance sheet is moderately healthy with low leverage, yet historical negative equity poses a risk. The company needs to address operational inefficiencies and improve cash generation to achieve sustainable financial health.Income Statement
The company has shown a revenue growth rate of 44.7% from 2023 to 2024, indicating strong top-line growth. However, the net profit margin is negative at -47.1% in 2024, showing ongoing profitability challenges. The gross profit margin improved slightly to 20.7%, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.45
Neutral
Balance Sheet
The debt-to-equity ratio is relatively low at 0.16, indicating conservative leverage. However, the return on equity is negative due to net losses. The equity ratio is 78.3%, suggesting a strong capital structure. Despite these strengths, the negative equity in previous years highlights potential financial instability.55
Neutral
Cash Flow
The free cash flow is negative and deteriorated by 6.1% from 2023 to 2024, indicating cash flow challenges. The operating cash flow to net income ratio is not favorable as both are negative, indicating inefficiencies in converting earnings into cash flows.40
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.98M | 5.52M | 5.62M | 1.41M | 0.00 |
| Gross Profit | 1.65M | 1.41M | 1.06M | 430.35K | 0.00 |
| EBITDA | -3.68M | -2.84M | -2.07M | -3.07K | -4.27K |
| Net Income | -3.76M | -2.94M | -2.12M | -3.28K | -4.27K |
Balance Sheet | |||||
| Total Assets | 3.68M | 4.92M | 2.32M | 536.89K | 3.00K |
| Cash, Cash Equivalents and Short-Term Investments | 2.40M | 3.28M | 3.34K | 100.01K | 3.00K |
| Total Debt | 452.08K | 248.10K | 934.84K | 148.66K | 3.00K |
| Total Liabilities | 800.76K | 910.07K | 1.61M | 544.04K | 7.17K |
| Stockholders Equity | 2.88M | 4.01M | 710.10K | -7.15K | -4.17K |
Cash Flow | |||||
| Free Cash Flow | -2.94M | -2.77M | -2.37M | -94.49K | 0.00 |
| Operating Cash Flow | -2.93M | -2.76M | -2.24M | -88.20K | 0.00 |
| Investing Cash Flow | -11.11K | -15.25K | -121.26K | -6.29K | 0.00 |
| Financing Cash Flow | 2.06M | 6.05M | 2.27M | 191.50K | 36.00K |
Syra Health Corp. Class A Technical Analysis
Positive
0.12
Price Trends
0.09
Positive
0.17
Negative
0.30
Negative
Market Momentum
>-0.01
Negative
59.76
Neutral
67.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and below the 200-day MA of 0.30, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.76 is Neutral, neither overbought nor oversold. The STOCH value of 67.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.
Syra Health Corp. Class A Risk Analysis
Syra Health Corp. Class A disclosed 46 risk factors in its most recent earnings report. Syra Health Corp. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Syra Health Corp. Class A Peers Comparison
Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | AU$2.58B | 3.33 | -57.47% | 2.48% | 36.73% | 13.67% | |
50 Neutral | $1.43M | ― | -94.29% | ― | 33.04% | 39.30% | |
45 Neutral | $3.86M | ― | -235.50% | ― | -49.76% | 96.81% | |
34 Underperform | $4.10M | ― | -105.70% | ― | -100.00% | 28.48% | |
| ― | $11.35M | ― | -221.23% | ― | ― | ― | |
| ― | $7.99M | ― | ― | ― | ― | ||
| ― | $4.03M | ― | -79.71% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
SYRA
Syra Health Corp. Class A
0.12
-1.15
-90.55%
NBY
NovaBay Pharma
0.65
-1.48
-69.48%
TTNP
Titan Pharmaceuticals
4.59
-1.19
-20.59%
ATNF
180 Life Sciences
2.81
0.53
23.25%
NLSP
NLS Pharmaceutics
2.20
-5.44
-71.20%
SPRC
SciSparc Ltd.
7.99
-3.34
-29.48%
Syra Health Corp. Class A Corporate Events
Executive/Board Changes
Syra Health Appoints Priya Prasad as Interim CEO
Neutral
Jun 17, 2025
On June 13, 2025, Syra Health Corp.’s Board of Directors terminated the employment agreement with CEO Deepika Vuppalanchi, initially established on April 5, 2021. Subsequently, on June 16, 2025, Priya Prasad, the company’s CFO and COO, was appointed as interim CEO, indicating a significant leadership transition within the company.
Executive/Board ChangesBusiness Operations and Strategy
Syra Health Corp. Initiates Search for New CEO
Neutral
May 20, 2025
On May 20, 2025, Syra Health Corp. announced that its Board of Directors has initiated a national search for a new CEO to succeed Dr. Deepika Vuppalanchi, who will remain as interim CEO until a successor is appointed. This leadership transition is part of a strategic plan to position the company for its next growth phase in the healthcare sector, with a focus on delivering accessible and affordable healthcare solutions. Dr. Vuppalanchi, a co-founder, is expected to continue supporting the company’s strategic direction and growth initiatives after the new CEO is appointed.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.